Boyds
Boyds is a UK-headquartered drug development consultancy founded in 2005 that provides regulatory affairs, clinical operations, medical affairs, and product development services to pharmaceutical, biotech, and medical device companies globally, with particular specialisation in advanced therapies and cell and gene therapies.
- Company typePrivate
- Founded2005
- HeadquartersCrewe, United Kingdom
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Boyds does
Boyds is a UK-headquartered drug development consultancy founded in 2005 by Professor Alan Boyd, operating as Boyds International Life Sciences Group Limited (registered in England and Wales). The firm provides integrated regulatory affairs, clinical and medical affairs, clinical operations, pharmaceutical due diligence, product development, and medical device consulting services to pharmaceutical companies, biotechs, medical device firms, and universities across the US, UK, and Europe. Its differentiation centres on advanced therapies (cell and gene therapies, ATMPs, orphan drugs) with documented support for multiple approved cell and gene therapies, 20+ years of regulatory experience working with FDA, EMA, and MHRA, and official EMA SME status enabling client fee reductions of up to 90%. The firm has been recognised with the Queen's Award for Enterprise (International Trade, 2018) and the TOPRA Award for Regulatory Excellence (2023).
Core capabilities are delivered through a team of experienced pharmaceutical physicians and regulatory experts, including senior leaders with prior experience at Pfizer, Merck, Astellas Pharma, Ferring Pharmaceuticals, and the MHRA's predecessor organisation. Underpinning technology infrastructure includes the LORENZ docuBridge regulatory information management system for eCTD publishing, electronic submissions, and regulatory document management. The firm also operates dedicated service lines such as 'B-Investor Ready' for early-stage biotech fundraising preparation, 'My Development TEAM' for fractional development team outsourcing, interim CMO support, and a thought leadership podcast ('Conversations in Drug Development').
The business model is professional services-based, generating revenue through project-based engagements, multi-year retainers, and interim staffing solutions. Pricing is custom and quote-based, varying by scope, team composition, and duration. The go-to-market motion is sales-led via direct outreach, supplemented by thought leadership content (podcasts, webinars, blog, case studies), industry events and conferences, and LinkedIn-driven engagement. The company is founder-led and privately held with no external funding rounds disclosed, growing organically across its four offices in Crewe (HQ), Cambridge, Pennsylvania, and Dublin.
Boyds firmographics
Firmographics- Name
- Boyds
- Legal name
- Boyds International Life Sciences Group Limited
- Website
- https://boydconsultants.com
- Company type
- Private
- Founded year
- 2005
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Boyds is a UK-headquartered drug development consultancy founded in 2005 that provides regulatory affairs, clinical operations, medical affairs, and product development services to pharmaceutical, biotech, and medical device companies globally, with particular specialisation in advanced therapies and cell and gene therapies.
- Ownership category
- akta.pro rank
Boyds industry classification
Industry- Product category
- Pharmaceutical Regulatory & Drug Development Consulting
- NAICS
- Other Scientific and Technical Consulting Services (54169), Management, Scientific, and Technical Consulting Services (5416), Research and Development in the Physical, Engineering, and Life Sciences (54171)
- SIC
- Services-Commercial Physical & Biological Research (8731), Services-Engineering, Accounting, Research, Management (8700)
- akta.pro primary industry
- Regulatory Strategy & Global Submissions (IND/CTA/NDA/BLA/MAA) (HLAGAKAA)
- akta.pro secondary industry
- Regulatory Strategy & IND/NDA/BLA Submissions Support (HLAIALAH)
Keywords
Where Boyds is headquartered
LocationHeadquarters
- HQ city
- Crewe
- HQ country
- United Kingdom
- HQ region
- Europe
Offices4 records
Markets served
Boyds business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Marketing or Sales, Operations
Revenue model
- Consulting Services: Boyds generates revenue through providing expert consultancy services across regulatory affairs, clinical operations, medical affairs, product development, and due diligence. Services are delivered through project-based engagements, retainers, and interim staffing solutions.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Custom consulting engagements |
Go-to-market motion2 records
Distribution channels1 record
Marketing channels9 records
Boyds product offering
Product offeringCore offering
Boyds is a global drug development consultancy that translates innovative scientific ideas into approved medicinal products. It provides expert consulting across regulatory affairs (FDA, EMA, MHRA submissions), clinical operations and biostatistics, medical affairs and interim CMO support, product development, pharmaceutical due diligence, CMC regulatory affairs, regulatory operations and publishing, and medical device consulting. The firm serves pharmaceutical, biotechnology, and medical device companies with particular depth in advanced therapies, cell and gene therapies, ATMPs, rare diseases, and oncology.
Product overview
Boyds is a global drug development consultancy that translates innovative ideas into medicinal products and treatments for patient benefit. Founded in 2005 by Professor Alan Boyd MBE, the firm operates as a unified consultancy offering integrated services rather than a software platform with discrete products. The service portfolio centers on Regulatory Affairs Consulting (covering FDA, EMA, MHRA filings), Clinical and Medical Affairs (medical monitoring, interim CMO support, scientific advice), Clinical Operations (biostatistics, project management, site monitoring, study start-up), Product Development (including Investor Readiness via B-Investor Ready, fractional CDO services), Regulatory Operations and Publishing (eCTD submissions, collaborative pathways like Project Orbis), Pharmaceutical Due Diligence, Early Access Programs with Real-World Data Collection, and Medical Device Consulting. The company also produces educational content through its 'Conversations in Drug Development' podcast. Boyds specializes in advanced therapies including cell and gene therapies, small molecules, biologics, and orphan drugs, with expertise across oncology, rare diseases, and ATMPs. Key differentiators include award-winning regulatory affairs (Queen's Award 2018, TOPRA Futures Award 2023), EMA SME status for client fee benefits, and dual presence across US, UK, and Ireland offices.
Differentiator
Problem solved
Functional benefit
Brands
- B-Investor Ready: A service offered by Boyds to help early-stage biotech companies prepare for investor readiness and secure funding.
- My Development TEAM
- Conversations in Drug Development
Products and services
- Regulatory Affairs Consulting Strategic and hands-on regulatory support across the full drug development lifecycle, working with FDA, EMA, MHRA, and global regulatory agencies to facilitate efficient development and approval of medicinal products. Targeted at pharmaceutical and biotechnology companies seeking expert regulatory strategy.
Quantifiable outcome
- 95%+ client satisfaction rate
- +1 more outcomes
Companies that use Boyds
Customer profileNamed customers3 records
Segments1 record
Ideal customer profiles4 records
Boyds technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Boyds partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered minor and core.
- MIAS PharmaminorListed as a partner in the Resources section. MIAS Pharma is a pharmaceutical industry partner providing regulatory and consulting services.
- StratagemminorListed as a partner in the Resources section. Stratagem is an intellectual property management partner.
- TherapeutAixminorListed as a partner in the Resources section. TherapeutAix is a strategic partner in therapeutics development.
- LORENZ docuBridgecoreBoyds has invested in the industry-leading regulatory information management system, LORENZ docuBridge, to enable full electronic submission, publishing, and regulatory document management. This is a core technology partnership for their regulatory operations services.
Scale indicators5 records
Recent moves9 records
Expansion highlights5 records
Boyds competitors and assessment
Company assessmentBroad incumbents
- Parexel International: Major global CRO with deep regulatory affairs and drug development consulting capabilities across pharma and biotech. Overlapping service scope with Boyds but at significantly larger scale and broader geographic reach.
- Charles River Laboratories: Large, established CRO/CDMO offering preclinical, clinical and manufacturing services across pharma and biotech. Overlaps with Boyds in early-stage drug development and regulatory affairs support, but as part of a much wider portfolio.
- Frontage Laboratories: Larger CRO/contract laboratory offering CMC, bioanalytical, preclinical and clinical services to pharma and biotech. Broader and more scaled than Boyds but overlapping in CMC regulatory affairs and drug development support.
- ICON plc: Top-tier global CRO providing clinical, regulatory, laboratory and consulting services across all phases of drug development. Overlaps with Boyds' clinical operations and regulatory consulting, but at vastly greater scale.
Direct peers
- Celerion: Clinical research organisation specialising in early-phase clinical research and bioanalytical services. Comparable for early-stage drug development engagements, particularly for biotech clients running first-in-human studies.
- Worldwide Clinical Trials: Mid-size global CRO providing clinical trial services including regulatory affairs, biostatistics and medical affairs across pharma and biotech. Direct competitor for clinical operations and regulatory consulting engagements.
- Clinipace Worldwide (now dMed): Mid-size CRO offering regulatory, clinical operations and biometrics services to biotech and pharma. Closely comparable in scale and service breadth to Boyds' clinical operations and biostatistics offerings.
- Pharmalex: Germany-based regulatory affairs, pharmacovigilance and quality consulting firm serving pharma, biotech and medical device companies. Directly comparable service portfolio (regulatory strategy, submissions, CMC) and similar mid-market positioning to Boyds.
- ProPharma Group: US-headquartered regulatory, compliance, clinical and quality consulting organisation serving pharma and biotech. Highly comparable in scope of regulatory and drug development consulting services, with broader scale than Boyds.
- NDA Group: Sweden-headquartered regulatory and pharmacovigilance consultancy serving pharma and biotech globally. The closest functional peer to Boyds — similar size, similar regulatory-affairs-and-drug-development focus, and overlapping client segments in early-stage biotech and ATMP developers.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Boyds social profiles
Digital presenceBoyds compliance and trust
Trust signalCompliance4 records
Boyds financial estimates
Financial estimateRevenue estimate
Valuation estimate
Boyds leadership team
Management profileNumber of profiles
Profiles9 records
Boyds funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Boyds M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Boyds
What does Boyds do?
Boyds is a global drug development consultancy that translates innovative scientific ideas into approved medicinal products. It provides expert consulting across regulatory affairs (FDA, EMA, MHRA submissions), clinical operations and biostatistics, medical affairs and interim CMO support, product development, pharmaceutical due diligence, CMC regulatory affairs, regulatory operations and publishing, and medical device consulting. The firm serves pharmaceutical, biotechnology, and medical device companies with particular depth in advanced therapies, cell and gene therapies, ATMPs, rare diseases, and oncology.
Is Boyds a public or private company?
Boyds is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Boyds founded?
Boyds was founded in 2005. It employs 11 to 50 people.
Where is Boyds based?
Boyds is headquartered in Crewe, United Kingdom, in the Europe region.
How does Boyds make money?
One revenue line is on record: consulting Services.
Who are Boyds's main competitors?
Broad incumbents on record are Parexel International, Charles River Laboratories, Frontage Laboratories and ICON plc. Direct peers are Celerion, Worldwide Clinical Trials, Clinipace Worldwide (now dMed), Pharmalex, ProPharma Group and NDA Group.
Does Boyds have an API?
No public API is recorded for Boyds.
What industry is Boyds in?
Boyds's product category is Pharmaceutical Regulatory & Drug Development Consulting. Its primary akta.pro industry code is HLAGAKAA, Regulatory Strategy & Global Submissions (IND/CTA/NDA/BLA/MAA), with a secondary code of HLAIALAH, Regulatory Strategy & IND/NDA/BLA Submissions Support. Its NAICS code is 54169 and its SIC code is 8731.